(click to expand)
When you purchase access to a research report from us, a window will appear with a link to your downloads from which you may access the report--or, you may click on this link.
An email will also be sent to the address you registered with, containing a link to the report from which you may download or upload it. If you have not received this email in your inbox, please check your spam folder.
If you are still having difficulties, please contact us directly.
Printing/sharing of our research reports with others is authorized to the extent it is not made widely accessible on a public domain.
If you have submitted a payment and we have granted access to one of our reports, then unfortunately we cannot cancel an order, nor provide a refund, as the product itself, which is the content of our research, shall be considered to have been "used" by you or your firm.
However, our services may be canceled at any time by sending us an email with the request.
We may be contacted directly with any questions that you have and will respond promptly.
Medical Research Collaborative, LLC ("MRC") is a start-up company that is in a state of flux. At any given point in time, there may be multiple members (executive and non-executive) of MRC that have attained a medical degree, a PhD, a degree in regulatory science, or a law degree, or there may be no members that have attained the aforementioned degrees. It is the intention of MRC to evolve into a research company that has a variety of experts that have earned the aforementioned, established degrees on its staff that serve as members involved in the research of healthcare companies.
The piece, entitled "AMRN: Market Headwinds and Inherent Weakness of the Vascepa IP," as well as any citizen petitions written under the MRC moniker, were wholly constructed by the President & CEO of MRC, who has extensive knowledge in various pharmaceutical/medical science topics, in regulatory science, and in patent law, but has not earned any of the aforementioned established degrees.
The goal of MRC is to make the research that we produce the focus; in our view, the work should stand or fall based on its own merits, including the peer-reviewed authorship of the scientists it cites. Further, the subject matter entailing our focus can at times be controversial, and the publication of reports on such result in the provocation of ad hominem attacks from investors in the companies we report on, distracting from the content of the work itself. A truly zealous antagonist that misconstrues s/he has been harmed by one of our reports could in some instances jeopardize the careers of certain members of MRC by harassing the establishments/firms at which they are employed (not to mention their family members). For these reasons, it is company policy that the identities of the members of MRC remain anonymous. If a member is named, that name is likely to be a pen name.